章若涵,李春艳.联合使用氯吡格雷及尿激酶行易化急诊PCI的疗效观察.[J].中南医学科学杂志.,2011,39(3):280-282.
联合使用氯吡格雷及尿激酶行易化急诊PCI的疗效观察
The Efficacy Study About Joint Use of Clopidogrel and Urokinase-line for Facilitated Emergency PCI
投稿时间:2010-09-07  
DOI:
中文关键词:  氯吡格雷  尿激酶  易化PCI
英文关键词:clopidogrel  urokinase  facilitated PCI
基金项目:
作者单位
章若涵1,李春艳2 1.南华大学 附属南华医院 心内科湖南 衡阳 4210022.南华大学 附属南华医院 超声室 
摘要点击次数: 651
全文下载次数: 951
中文摘要:
      目的比较易化急诊经皮冠状动脉介入治疗术(PCI)与直接急诊PCI,评价易化PCI的有效性及安全性。方法将急诊PCI患者分为易化PCI治疗及直接PCI治疗,前者于术前给予氯吡格雷及尿激酶治疗,后者术前仅予氯吡格雷治疗,比较术中“罪犯”血管开通率,术后30天出血事件及主要心血管事件(MACE)发生率。结果易化PCI治疗与直接PCI治疗比较,术中“罪犯”血管开通率、30天内主要终点事件发生率和出血事件发生率之间差异无显著性。结论联合药物易化急诊PCI治疗虽然能提高术后血流TIMI分级,但不能有效减少术后30天MACE发生率,且出血事件有增加趋势。
英文摘要:
      ObjectiveCompared facilitated emergency PCI with direct emergency PCI,and estimate the effectiveness and security of facilitated emergency PCI.MethodsThe patients were divided into experiment and control groups,the former was given clopidogrel and urokinase before surgery,the latter was only treated with clopidogrel before surgery,compared “criminal” artery patency rate,bleeding events and the incidence of major advance cardiovascular events(MACE)within 30 days after PCI.ResultsCompared with direct emergency PCI,criminal vascular patency rate,incidence of MACE within 30 day and bleeding events have not significantly different in facilitated emergency PCI group.Conclusion Compared with direct emergency PCI,facilitated emergency PCI can improve the TIMI level,but can not effectively decrease the incidence of MACE,and the bleeding event show an increasing trend.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=B4E9CAE4DD6ECECF3FF4DCDC98FAD03D8D81AABFCF140CE39B7D21BFB470EF63BB06C146E9A311770C3E3BFC12855A5B516FA8EFCA7049D2B769CB041792B4A3C0494F309ECCA1B7154147CF4D531D97D2BC9AB537AB1DC28EACD9DEDAEAEF698508AB44ADDDC23F&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=9377ED8094509821&aid=DD26710B4E10EE67DE32CFAFA1FE4360&vid=&iid=38B194292C032A66&sid=5D8C08279A19B0D4&eid=4133DDB79B497495&fileno=20110311&flag=1&is_more=0">